25 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
24 Mar 20
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
8:45am
(UC). The primary goals of the study are to assess safety, tolerability, PK, PD and target engagement in patients with active disease. Gossamer expects
8-K
EX-99.1
GOSS
Gossamer Bio Inc
9 Aug 21
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
4:27pm
of the virtual ERS Congress. ePoster details:
◦ePoster Title: Evidence of Target Engagement and Pathway Modulation: Biomarker Analysis of the Phase 1b
8-K
EX-99.1
GOSS
Gossamer Bio Inc
12 May 20
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
to be unrelated to study drug.
PK / PD and Target Engagement: The gut-targeted pharmacokinetic (PK) profile of GB004 was shown with rapid clearance from
DRS
EX-10.13
GOSS
Gossamer Bio Inc
11 Oct 18
Draft registration statement
12:00am
, that such engagement will be at the Indemnified Party’s own expense unless (i) the engagement thereof has been specifically requested by the Indemnifying Party
8-K
EX-10.1
GOSS
Gossamer Bio Inc
20 Jul 23
Gossamer Bio Announces $212 Million Private Placement Financing
4:01pm
of the Securities to the Purchasers on the terms and subject to the conditions set forth in this Agreement, the Company has entered into engagement … letters (the “Engagement Letters”), with each of Leerink Partners LLC, Piper Sandler & Co. and H.C. Wainwright & Co., LLC (the “Placement Agents
S-1
EX-10.17
3vc7pi0jxpz6385of
21 Dec 18
IPO registration
4:39pm
8-K
EX-3.1
iy63zvhtro17a
27 Nov 23
Departure of Directors or Certain Officers
4:01pm
S-1/A
EX-3.4
zbffrt9xms njnxsa0lf
23 Jan 19
IPO registration (amended)
4:39pm
PRE 14A
svmkdfz
17 Apr 23
Preliminary proxy
4:01pm
10-K
p12ftr1 sng2
22 Mar 19
Annual report
4:45pm
S-1/A
oiry3ha
23 Jan 19
IPO registration (amended)
4:39pm